cresco labs - CRLBF

CRLBF

Close Chg Chg %
0.87 0.04 4.71%

Open Market

0.91

+0.04 (4.71%)

Volume: 193.71K

Last Updated:

Apr 1, 2026, 12:28 PM EDT

Company Overview: cresco labs - CRLBF

CRLBF Key Data

Open

$0.81

Day Range

0.81 - 0.95

52 Week Range

0.43 - 2.30

Market Cap

$313.23M

Shares Outstanding

360.03M

Public Float

334.97M

Beta

1.15

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.38

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.09M

 

CRLBF Performance

1 Week
 
4.05%
 
1 Month
 
-12.12%
 
3 Months
 
-29.27%
 
1 Year
 
46.84%
 
5 Years
 
-93.30%
 

CRLBF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About cresco labs - CRLBF

Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.

CRLBF At a Glance

Cresco Labs, Inc.
600 West Fulton Street
Chicago, Illinois 60661
Phone 1-312-929-0993 Revenue 655.85M
Industry Agricultural Commodities/Milling Net Income -135,408,000.00
Sector Process Industries Employees N/A
Fiscal Year-end 12 / 2026
View SEC Filings

CRLBF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.656
Price to Book Ratio 1.281
Price to Cash Flow Ratio 5.90
Enterprise Value to EBITDA 5.454
Enterprise Value to Sales 1.273
Total Debt to Enterprise Value 0.70

CRLBF Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 16.814
Total Asset Turnover 0.514

CRLBF Liquidity

Current Ratio 2.588
Quick Ratio 1.603
Cash Ratio 0.909

CRLBF Profitability

Gross Margin 46.412
Operating Margin 14.848
Pretax Margin -14.549
Net Margin -20.646
Return on Assets -10.609
Return on Equity -33.217
Return on Total Capital -14.645
Return on Invested Capital -13.592

CRLBF Capital Structure

Total Debt to Total Equity 171.586
Total Debt to Total Capital 63.179
Total Debt to Total Assets 48.79
Long-Term Debt to Equity 164.814
Long-Term Debt to Total Capital 60.686
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cresco Labs - CRLBF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
842.68M 770.89M 724.34M 655.85M
Sales Growth
+2.56% -8.52% -6.04% -9.46%
Cost of Goods Sold (COGS) incl D&A
456.30M 433.06M 381.66M 351.46M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
57.73M 69.30M 65.99M 55.74M
Depreciation
47.37M 62.26M 58.89M 49.35M
Amortization of Intangibles
10.36M 7.05M 7.11M 6.39M
COGS Growth
+4.43% -5.09% -11.87% -7.91%
Gross Income
386.38M 337.83M 342.68M 304.39M
Gross Income Growth
+0.42% -12.57% +1.44% -11.17%
Gross Profit Margin
+45.85% +43.82% +47.31% +46.41%
2022 2023 2024 2025 5-year trend
SG&A Expense
309.86M 259.81M 223.69M 207.01M
Research & Development
- - - -
-
Other SG&A
309.86M 259.81M 223.69M 207.01M
SGA Growth
+10.58% -16.15% -13.90% -7.45%
Other Operating Expense
- 17.75M 14.83M 8.59M
Unusual Expense
139.20M 150.16M 2.39M 141.79M
EBIT after Unusual Expense
(80.44M) (86.97M) 108.02M (44.42M)
Non Operating Income/Expense
12.05M 3.31M (59.74M) 9.02M
Non-Operating Interest Income
679.00K 2.42M 2.92M 3.75M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
58.52M 63.24M 58.90M 60.03M
Interest Expense Growth
+12.21% +8.08% -6.87% +1.91%
Gross Interest Expense
58.52M 63.24M 58.90M 60.03M
Interest Capitalized
- - - -
-
Pretax Income
(126.91M) (146.90M) (10.62M) (95.42M)
Pretax Income Growth
+50.34% -15.76% +92.77% -798.85%
Pretax Margin
-15.06% -19.06% -1.47% -14.55%
Income Tax
88.94M 32.95M 49.87M 44.62M
Income Tax - Current - Domestic
105.94M 46.19M 49.86M 48.77M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(18.19M) (41.99M) (997.00K) (4.15M)
Income Tax - Deferred - Foreign
- 1.19M 28.75M 1.01M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(215.84M) (179.85M) (60.49M) (140.04M)
Minority Interest Expense
(3.80M) (4.33M) 13.95M (4.64M)
Net Income
(212.05M) (175.52M) (74.44M) (135.41M)
Net Income Growth
+33.65% +17.22% +57.59% -81.91%
Net Margin Growth
-25.16% -22.77% -10.28% -20.65%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(212.05M) (175.52M) (74.44M) (135.41M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(212.05M) (175.52M) (74.44M) (135.41M)
EPS (Basic)
-0.7112 -0.542 -0.2155 -0.3814
EPS (Basic) Growth
+41.62% +23.79% +60.24% -76.98%
Basic Shares Outstanding
298.16M 323.82M 345.47M 355.01M
EPS (Diluted)
-0.7112 -0.542 -0.2155 -0.3814
EPS (Diluted) Growth
+41.62% +23.79% +60.24% -76.98%
Diluted Shares Outstanding
298.16M 323.82M 345.47M 355.01M
EBITDA
116.49M 132.50M 176.41M 153.12M
EBITDA Growth
-12.74% +13.74% +33.14% -13.20%
EBITDA Margin
+13.82% +17.19% +24.35% +23.35%

Snapshot

Average Recommendation BUY Average Target Price 1.854
Number of Ratings 6 Current Quarters Estimate -0.02
FY Report Date 06 / 2026 Current Year's Estimate -0.075
Last Quarter’s Earnings -0.035 Median PE on CY Estimate N/A
Year Ago Earnings -0.35 Next Fiscal Year Estimate -0.048
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 6 5
Mean Estimate -0.02 -0.02 -0.08 -0.05
High Estimates 0.02 0.02 0.08 0.10
Low Estimate -0.04 -0.04 -0.14 -0.11
Coefficient of Variance -141.42 -150.29 -108.57 -177.63

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Cresco Labs in the News